Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.4
Journals
Medicina
Special Issues
New Insights into Heart Failure Management and Treatment
share announcement

New Insights into Heart Failure Management and Treatment

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 15 January 2027 | Viewed by 1623

Special Issue Editors

Dr. Alejandro N. Barbagelata

E-Mail Website
Guest Editor
1. Catholic University of Argentina, Buenos Aires, Argentina
2. Duke University School of Medicine, Durham, NC 27708, USA
Interests: acute myocardial infarction and heart failure; percutaneous and surgical devices in heart failure
Dr. Edgardo J. Kaplinsky

E-Mail Website
Guest Editor
Cardiology Unit, Medicine Department, Hospital Municipal de Badalona, 08911 Badalona, Spain
Interests: heart failure; cardiomyopathies; heart transplantation; chronic clinical cardiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Heart failure remains a major global health challenge, affecting millions of individuals worldwide and representing a leading cause of hospitalization and mortality. Despite advances in cardiovascular medicine, the burden of heart failure continues to grow due to ageing populations, the increasing prevalence of risk factors like hypertension and diabetes, and improved survival from acute cardiac events.

This Special Issue, entitled "New Insights into Heart Failure Management and Treatment," delves into the latest research and clinical innovations seeking to address this complex syndrome. It highlights novel therapeutic approaches, including pharmacological advancements and device-based treatments, updated clinical guidelines, and cutting-edge diagnostic techniques that enable earlier detection and more personalized care.

Emphasis is placed on multidisciplinary management models that integrate cardiology, primary care, and allied health services to improve patient quality of life and reduce hospital readmissions. By synthesizing emerging evidence and expert perspectives, this Issue seeks to inform clinicians, researchers, and healthcare providers about future directions in heart failure treatment and the critical need for ongoing innovation to mitigate its growing impact.

Dr. Alejandro N. Barbagelata
Dr. Edgardo J. Kaplinsky
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • cardiovascular disease
  • treatment advances
  • management strategies
  • personalized medicine
  • clinical guidelines
  • diagnostic innovations
  • multidisciplinary care
  • emerging therapies
  • patient outcomes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 847 KB  
Article
RDW-to-Albumin Ratio as a Simple Biomarker for Early Mortality Risk After LVAD Implantation
by İbrahim Demir, Bilge Ecemiş, Ayşe Zorba, Selinsu Güleşce, Yahya Yıldız, İbrahim Oğuz Karaca and Korhan Erkanlı
Medicina 2026, 62(5), 853; https://doi.org/10.3390/medicina62050853 - 30 Apr 2026
Viewed by 276
Abstract
Background and Objectives: Early risk stratification remains challenging in patients undergoing left ventricular assist device (LVAD) implantation. Red cell distribution width (RDW) and serum albumin reflect systemic stress and nutritional reserve; their ratio (RDW-to-albumin ratio, RAR) may provide a simple preoperative index. We [...] Read more.
Background and Objectives: Early risk stratification remains challenging in patients undergoing left ventricular assist device (LVAD) implantation. Red cell distribution width (RDW) and serum albumin reflect systemic stress and nutritional reserve; their ratio (RDW-to-albumin ratio, RAR) may provide a simple preoperative index. We evaluated whether preoperative RAR is associated with early mortality after LVAD implantation. Materials and Methods: We conducted a retrospective cohort study of LVAD recipients (2019–2025). RAR was calculated as RDW (%) divided by albumin (g/dL) from preoperative blood tests obtained 24–48 h before surgery. The primary endpoint was in-hospital mortality. The secondary endpoint was 90-day survival. In-hospital mortality was analyzed using logistic regression with parsimonious adjustment for INTERMACS high-risk status (profiles 1–2 vs. 3–7); penalized regression was used to reduce small-sample bias. Discrimination was assessed using receiver operating characteristic (ROC) analysis. Ninety-day survival was evaluated using Cox proportional hazards models. Results: Forty-seven patients were included (37 survivors; 10 in-hospital deaths). Higher RAR was associated with increased odds of in-hospital mortality and remained significant after adjustment for INTERMACS high-risk status (OR 1.68, 95% CI 1.04–2.90). INTERMACS high-risk status was strongly associated with in-hospital mortality (OR 17.89, 95% CI 3.19–138.07). RAR demonstrated good discrimination for in-hospital mortality (AUC 0.801, 95% CI 0.648–0.955). For 90-day survival, RAR showed a borderline association in unadjusted analysis (HR 1.28, 95% CI 0.98–1.68) and was not significant after adjustment (HR 1.20, 95% CI 0.89–1.63). Conclusions: In this small single-center cohort, preoperative RAR was independently associated with in-hospital mortality after LVAD implantation. These findings should be considered hypothesis-generating and require external validation. Full article
(This article belongs to the Special Issue New Insights into Heart Failure Management and Treatment)
►▼ Show Figures

Figure 1

17 pages, 735 KB  
Article
Comparative Cardiovascular Outcomes of SGLT2i Plus Low-Dose of Conventional Triple Therapy Versus High-Dose of Conventional Triple Therapy for Heart Failure with Reduced Ejection Fraction (HFrEF): A Retrospective Cohort Study
by Suwat Khamboonruang, Parita Bunditboondee, Pongpun Jittham and Surarong Chinwong
Medicina 2026, 62(4), 781; https://doi.org/10.3390/medicina62040781 - 17 Apr 2026
Viewed by 956
Abstract
Background and Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular (CV) death and heart failure hospitalizations (HFH) in patients with heart failure with reduced ejection fraction (HFrEF). However, data regarding their use in combination with different doses of guideline-directed medical therapy (GDMT) [...] Read more.
Background and Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular (CV) death and heart failure hospitalizations (HFH) in patients with heart failure with reduced ejection fraction (HFrEF). However, data regarding their use in combination with different doses of guideline-directed medical therapy (GDMT) remain limited. This study aimed to evaluate whether SGLT2i combined with low-dose conventional triple therapy is non-inferior to high-dose conventional triple therapy in preventing adverse cardiovascular outcomes. Materials and Methods: This retrospective observational study included 334 patients with HFrEF treated between 31 March 2018 and 31 March 2024. Of these, 110 received SGLT2i plus low-dose conventional triple therapy, and 224 received high-dose conventional triple therapy. A non-inferiority framework was applied to compare outcomes between groups. The primary endpoint was a composite of CV death and HFH, while secondary endpoints included the individual components. Results: The composite endpoint occurred more frequently in the SGLT2i plus low-dose group. After inverse probability of treatment weighting and multivariable Cox analysis, this group demonstrated a significantly higher risk of the composite outcome (adjusted HR 4.10, 95% CI 2.07–8.13; p < 0.001). CV death was similar between groups; however, HFH was significantly more frequent in the SGLT2i plus low-dose group. Conclusions: In patients with HFrEF, SGLT2i combined with low-dose conventional triple therapy did not demonstrate comparable clinical outcomes to high-dose conventional triple therapy in reducing CV death and HFH, particularly in patients with a higher baseline burden of disease severity. These findings underscore the importance of optimizing background GDMT dosing alongside the incorporation of SGLT2i into clinical practice. Full article
(This article belongs to the Special Issue New Insights into Heart Failure Management and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop